Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


Purpose:

To determine if rituximab administered after allogeneic transplantation decreases the incidence of chronic graft-vs-host disease (cGvHD)


Study summary:

To test if prophylactic anti-B-cell therapy (weekly rituximab) given within 60 to 90 days after allogeneic transplantation will decrease allogeneic donor B-cell immunity and possibly the incidence of chronic graft-vs-host disease (cGvHD).


Criteria:

Recipient Inclusion Criteria: - Between 18 and 76 years of age - Chronic lymphocytic leukemia (CLL): - Unmutated IgG VH gene status - Mutated IgG VH genes (> 2% nucleotide change compared to somatic sequence) - Complete remission benefit most from allogeneic hematopoietic stem cell transplant (HSCT). (Physicians will be encouraged to provide aggressive chemotherapy prior to nonmyeloablative transplantation.) - Mantle cell lymphoma (MCL): Transplant physicians believe subject would benefit from allogeneic HSCT. - Adequate renal (Cr < 2.4 mg/dL) and hepatic (Bilirubin < 3.0 mg/dL, Aspartate aminotransferase (AST) < 100 IU) function. - Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment. - All subjects must provide written informed consent Donor Inclusion Criteria: - Genotypically or phenotypically human leukocyte antigen (HLA)-identical. - Age < 76 unless cleared by institutional PI - Capable of giving written, informed consent. - Must consent to peripheral blood stem cell (PBSC) mobilization with G-CSF and apheresis Recipient Exclusion Criteria: - Recipient has a 9 of 10 or 10 of 10 HLA identical donor (high resolution molecular genotyping at HLA A, B, C and DrB1, and DQ) - Pregnancy - Lactating - Serious uncontrolled infection - HIV seropositivity - Hepatitis B or C seropositivity - Cardiac function: ejection fraction < 40% or uncontrolled cardiac failure - Pulmonary: Diffusing capacity - carbon monoxide (DLCO) < 50% predicted - Liver function abnormalities: elevation of bilirubin to ≥ 3 mg/dL and/or AST > 100 - Renal: creatinine > 2.4 - Karnofsky performance score ≤ 60% - Patients with poorly controlled hypertension (systolic blood pressure > 150 or diastolic blood pressure > 90 repeatedly). - Known life-threatening hypersensitivity to rituximab or other anti-B cell antibodies. - Inability to comply with the allogeneic transplant treatment. - Uncontrolled central nervous system (CNS) involvement with disease Donor Exclusion Criteria: - Identical twin to subject - Contra-indication to subcutaneous G-CSF at a dose of 16 mg/kg/d for 5 consecutive days - Serious medical or psychological illness - Prior malignancy within the preceding five years, with the exception of non-melanoma skin cancers. - HIV seropositivity


NCT ID:

NCT00186628


Primary Contact:

Principal Investigator
David Miklos
Stanford University


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.